PROCEPT BioRobotics outlines $390M-$410M revenue target for 2026 as pricing discipline and commercial realignment reshape outlook
Source: SeekingAlpha
2026-02-26 12:48:42 ET
More on Procept
- PROCEPT BioRobotics Corporation (PRCT) Q4 2025 Earnings Call Transcript
- PROCEPT BioRobotics Corporation (PRCT) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
- Procept GAAP EPS of -$0.53 misses by $0.20, revenue of $76.4M misses by $17.3M
- Seeking Alpha’s Quant Rating on Procept
- Historical earnings data for Procept
Read the full article on Seeking Alpha
For further details see:
PROCEPT BioRobotics outlines $390M–$410M revenue target for 2026 as pricing discipline and commercial realignment reshape outlook
PROCEPT BioRobotics Corporation
NASDAQ: PRCT
PRCT Trading
-7.62% G/L:
$23.40 Last:
1,085,806 Volume:
$24.06 Open:
PRCT Latest News
March 08, 2026 07:40:00 pm
PRCT Investors Have Opportunity to Join PROCEPT BioRobotics Corporation Fraud Investigation with the Schall Law Firm
March 03, 2026 03:44:00 pm
Lost Money on PROCEPT BioRobotics Corporation (PRCT)? Contact Levi & Korsinsky About Fraud Investigation
PRCT Stock Data
$1,673,563,741
52,190,602
2.22%
92
N/A
Medical Equipment & Supplies
Healthcare
US
San Jose
